- Home
- Shop
- New Categories
- New Blog
- Contact Us
- Cart
- Login
- Register
Select the image to view it full size.
Product details
Catalog number BNC402646-100
Price for BNC402646-100
Size / count 1x 100 µL
CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression, dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in Mouse tumor models, and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
The catalog number for CD73 (Immuno-Oncology Target) (NT5E/2646), CF640R conjugate, 0.1mg/mL is BNC402646-100.
CD73 (Immuno-Oncology Target) (NT5E/2646), CF640R conjugate, 0.1mg/mL is available in the following size(s): 1x 100 µL.
CD73 (Immuno-Oncology Target) (NT5E/2646), CF640R conjugate, 0.1mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
CD73 (Immuno-Oncology Target) (NT5E/2646), CF640R conjugate, 0.1mg/mL is manufactured by Biotium.
Estimated delivery time for CD73 (Immuno-Oncology Target) (NT5E/2646), CF640R conjugate, 0.1mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for CD73 (Immuno-Oncology Target) (NT5E/2646), CF640R conjugate, 0.1mg/mL is available here: https://cdn.gentaur.com/products/37/68dd029c061270361e1022df/msds/bnc402646-100.pdf.
CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in pr
Some products, including certain cell lines, plasmids, and tissue cultures, are subject to intellectual property terms and may require an MTA before we can ship. We’ll inform you in advance if this product requires one, and additional handling fees may apply.
Provide the catalogue number, product name, lot number, and your experimental results to our technical support team. They’ll investigate and, if needed, escalate to the manufacturer, provided the product was used before expiry and stored correctly.
Isotype information such as IgG1 or IgG2a is listed in the product specifications on the datasheet, relevant for selecting compatible detection reagents.
